Claims
- 1. A method for treating a fungal infection or yeast infection in a mammal, the method comprising administering to the mammal in need of such treatment or at risk thereof a therapeutically effective amount of lupeol,
- 2. The method according to claim 1, wherein the fungal infection or yeast infection is caused by at least one dermatophytic fungus.
- 3. The method according to claim 2, wherein the fungal infection is caused by a fungus of the genus Blastomyces, Candida, Cryptococcus, Epidermophyton, Microsporum, Trichophyton, or Pityrosporum.
- 4. The method according to claim 2, wherein the fungus is Blastomyces dermatidis, Candida albicans, Candida guilliermoundi, Cryptococcus neoformans Microsporum canis, Microsporum audouinii, Microsporum gypseum, Trichophyton tonsuran, Trichophyton rubrum, Trichophyton mentagrophyte, Epidermophyton floccosum, Pityrosporum ovale, or a combination thereof.
- 5. The method according to claim 1, wherein the mammal is a human.
- 6. The method according to claim 1, wherein the therapeutically effective amount is about 0.1 μg to about 500 mg.
- 7. The method according to claim 2, wherein the fungal infection is caused by Blastomyces dermatidis or Cryptococcus neoformans.
- 8. The method according to claim 2, wherein the yeast infection is caused by Pityrosporum ovale.
- 9. The method according to claim 1, further comprising administering lupeol either sequentially or simultaneously with a second therapeutic agent.
- 10. The method according to claim 9, wherein the second therapeutic agent is at least one of an anti-fungal agent, an anti-yeast agent, an antibiotic agent, or an antiviral agent.
- 11. The method according to claim 1, wherein the therapeutically effective amount of lupeol is administered as a topical formulation.
- 12. A method of inhibiting or killing a fungus or yeast, the method comprising contacting the fungus or yeast with an effective anti-fungal or anti-yeast amount of lupeol.
- 13. The method according to claim 12, wherein the fungus is a dermatophytic fungus selected from Blastomyces, Candida, Cryptococcus, Epidermophyton, Microsporum, Trichophyton, or Pityrosporum.
- 14. The method according to claim 12, wherein the dermatophytic fungus is Blastomyces dermatidis, Candida albicans, Candida guilliermoundi, Cryptococcus neoformans Microsporum canis, Microsporum audouinii, Microsporum gypseum, Trichophyton tonsuran, Trichophyton rubrum, Trichophyton mentagrophyte, Epidermophyton floccosum, Pityrosporum ovale, or a combination thereof.
- 15. The method according to claim 12, wherein the fungus is Candida albicans or Candida guilliermoundi.
- 16. The method according to claim 12, wherein the fungus is Blastomyces dermatidis or Cryptococcus neoformans.
- 17. The method according to claim 12, wherein the yeast is Pityrosporum ovale.
- 18. The method according to claim 11, wherein the lupeol is applied using a topical composition.
- 19. The method according to claim 11, further comprising contacting the fungus or yeast either sequentially or simultaneously with a second therapeutic agent.
- 20. The method according to claim 19, wherein the second therapeutic agent is at least one of an anti-fungal agent, anti-yeast agent, an antibiotic agent, or an antiviral agent.
- 21. A method for enhancing skin appearance, the method comprising administering to the skin a topical composition that comprises a pharmaceutically or cosmetically suitable carrier and a cosmetically effective amount of lupeol.
- 22. The method according to claim 21, wherein the lupeol is present in a concentration of about 0.001 μg/ml to about 5000 μg/ml.
- 23. The method according to claim 21, wherein lupeol is present in a concentration of about 12.5 μg/ml to about 1000 μg/ml.
- 24. The method according to claim 21, wherein lupeol is present in a concentration of up to about 10 wt. %.
- 25. A method for enhancing skin appearance, the method comprising administering to the skin a topical composition that comprises a pharmaceutically or cosmetically suitable carrier and at least about 1 μM lupeol.
- 26. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of lupeol.
- 27. A cosmetic composition comprising a cosmetically or pharmaceutically acceptable carrier and a cosmetically effective amount of lupeol.
PRIORITY OF INVENTION
[0001] This application is a continuation-in-part application of U.S. application Ser. No. 09/969,553, filed on Oct. 1, 2001, which claims the benefit of U.S. provisional application No. 60/237,756, filed on Sep. 29, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60237756 |
Sep 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09969553 |
Oct 2001 |
US |
Child |
10431351 |
May 2003 |
US |